Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mangoceuticals (MGRX) Cost of Revenue (2023 - 2025)

Historic Cost of Revenue for Mangoceuticals (MGRX) over the last 3 years, with Q3 2025 value amounting to $2359.0.

  • Mangoceuticals' Cost of Revenue fell 8903.05% to $2359.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $67242.0, marking a year-over-year decrease of 4634.68%. This contributed to the annual value of $93296.0 for FY2024, which is 3977.02% down from last year.
  • As of Q3 2025, Mangoceuticals' Cost of Revenue stood at $2359.0, which was down 8903.05% from $18815.0 recorded in Q2 2025.
  • Mangoceuticals' Cost of Revenue's 5-year high stood at $53362.0 during Q4 2023, with a 5-year trough of $2359.0 in Q3 2025.
  • In the last 3 years, Mangoceuticals' Cost of Revenue had a median value of $23753.0 in 2023 and averaged $26737.0.
  • Within the past 5 years, the most significant YoY rise in Mangoceuticals' Cost of Revenue was 1895.65% (2025), while the steepest drop was 8903.05% (2025).
  • Quarter analysis of 3 years shows Mangoceuticals' Cost of Revenue stood at $53362.0 in 2023, then plummeted by 60.03% to $21331.0 in 2024, then plummeted by 88.94% to $2359.0 in 2025.
  • Its last three reported values are $2359.0 in Q3 2025, $18815.0 for Q2 2025, and $24737.0 during Q1 2025.